Skip to main content

Fiscal Wizard · Single-issue tearsheet

ERAS / Jun 21, 2026 Run #7510

ERAS

Erasca, Inc.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Composite verdict

D 31.1 / 100
Bearish setup · Reversal 8 drivers · 1 gate blocking
  • Chaikin Money Flow
  • Accumulation/Distribution Line
  • Engulfing
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 163rd of 598 in Biotechnology

rescore-sweep
Technical synthesis
Bull 0%Evidence: High · 23 signals100% Bear
Momentum Bearish 34Mean-reversion Bearish 30

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

51.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Free Cash Flow Yield 0
Greenblatt EY 76
P/B 25
Return on Assets 72
Return on Equity 25

Technicals Bearish

10.9 / 100

Bearish setup leads (Chaikin Money Flow, Accumulation/Distribution Line, Engulfing); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 5
Accumulation/Distribution Line 12
Engulfing 15

Risk Gates

1 blocking 7 caution

1 guard active, 17 signals gated.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Sloan Ratio Caution

Visual accruals-quality flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ERAS.